Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. 2006

Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1 Habikino, Habikino, Osaka 583-8588, Japan. m-koba@hbk.pref.osaka.jp

BACKGROUND The combination of chemotherapy and thoracic radiation therapy (TRT) is considered as a standard treatment for locally advanced non-small-cell lung cancer (NSCLC). Although the frequent interaction of anticancer agents and irradiation may produce stronger radio-sensitizing effects, the daily administration of these agents is complicated. We therefore used weekly administration of these agents, and conducted a phase I study of weekly cisplatin, vinorelbine, and concurrent TRT. The purpose of this study was to identify the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT), and the recommended dose of this treatment. METHODS Patients with locally advanced NSCLC were enrolled in this study. Both cisplatin and vinorelbine were given intravenously on a weekly schedule for 6 weeks, starting on the first day of TRT, i.e., on days 1, 8, 15, 22, 29, and 36. The total dose of TRT was 60 Gy. The dose of cisplatin was fixed at 20 mg/m(2) per week. The starting dose of vinorelbine was 15 mg/m(2) per week (dose level 1). RESULTS Nine patients were enrolled in this study. All three patients at dose level 1 experienced DLTs. We decreased the dose of vinorelbine to 10 mg/m(2) per week (dose level 0). Two of the six patients at dose level 0 experienced DLTs. Therefore, dose level 1 was considered as the MTD, and dose level 0 as the recommended dose. The DLTs of this treatment were esophagitis, fatigue, infection, and hyponatremia. CONCLUSIONS The recommended dose of cisplatin is 20 mg/m(2) per week and that of vinorelbine is 10 mg/m(2) per week with standard TRT. A phase II study of this treatment is warranted.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D011838 Radiation-Sensitizing Agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. Radiation Sensitizer,Radiosensitizing Agent,Radiosensitizing Agents,Agents, Radiation-Sensitizing,Radiation Sensitizers,Radiation Sensitizing Agents,Radiation-Sensitizing Drugs,Radiation-Sensitizing Effect,Radiation-Sensitizing Effects,Radiosensitizing Drugs,Radiosensitizing Effect,Radiosensitizing Effects,Agent, Radiosensitizing,Agents, Radiation Sensitizing,Agents, Radiosensitizing,Drugs, Radiation-Sensitizing,Drugs, Radiosensitizing,Effect, Radiation-Sensitizing,Effect, Radiosensitizing,Effects, Radiation-Sensitizing,Effects, Radiosensitizing,Radiation Sensitizing Drugs,Radiation Sensitizing Effect,Radiation Sensitizing Effects,Sensitizer, Radiation,Sensitizers, Radiation,Sensitizing Agents, Radiation
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
August 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
September 2003, British journal of cancer,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
December 2001, International journal of radiation oncology, biology, physics,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
August 2005, Radiation medicine,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
August 1997, Seminars in oncology,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
January 2004, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
March 1999, British journal of cancer,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
April 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
March 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,
Masashi Kobayashi, and Kaoru Matsui, and Tomonori Hirashima, and Takashi Nitta, and Shinji Sasada, and Takuhito Tada, and Kazuo Minakuchi, and Mitsugi Furukawa, and Yoshitaka Ogata, and Ichiro Kawase
January 2011, Frontiers in oncology,
Copied contents to your clipboard!